Sanofi takes aim at J&J's myeloma star Darzalex with latest Sarclisa trial win

For Sanofi, a recent FDA nod for Sarclisa marks its return to oncology. Now, the French pharma is touting a clinical victory that puts the drug on track to a new multiple myeloma use.

Adding Sarclisa to Amgen’s Kyprolis and dexamethasone significantly cut the risk of cancer progression or death compared with the Kyprolis-corticosteroid pairing alone in patients with relapsed multiple myeloma, Sanofi said Tuesday.